Synthetic SiRNA delivery: Progress and prospects

Methods in Molecular Biology

Volumn 1364, Issue , 2016, Pages 291-310

  Roberts, Thomas C ^a   Ezzat, Kariem ^a   El Andaloussi, Samir ^a   Weinberg, Marc S ^a  

^a NONE

Author keywords

Cell penetrating peptides; Lipid nanoparticles; Lipidoids; SiRNA Conjugates; SiRNA delivery

Indexed keywords

CELL PENETRATING PEPTIDE; MACROGOL; N ACETYLGALACTOSAMINE; NANOPARTICLE; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; DRUG CARRIER;

CHEMICAL MODIFICATION; CONJUGATION; DRUG FORMULATION; GENE EXPRESSION; GENE SILENCING; NONVIRAL GENE DELIVERY SYSTEM; POSTTRANSCRIPTIONAL GENE SILENCING; RNA INTERFERENCE; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; GENETICS; SYNTHESIS;

ANIMALS; DRUG CARRIERS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; RNA, SMALL INTERFERING;

EID: 84944474817     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3112-5_23     Document Type: Chapter

References (147)

1. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498
3. Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366
4. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123:607-620
5. Rand TA, Petersen S, Du FH, Wang XD (2005) Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123:621-629
6. Liu JD, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-1441
7. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23:222-226
8. Yu DB, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE, Lima WF, Crooke ST, Prakash TP, Corey DR (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150:895-908
9. Lima WF, Prakash TP, Murray HM, Kinberger GA, Li WY, Chappell AE, Li CS, Murray SF, Gaus H, Seth PP, Swayze EE, Crooke ST (2012) Single-stranded siRNAs activate RNAi in animals. Cell 150:883-894
10. Byrne M, Tzekov R, Wang Y, Rodgers A, Cardia J, Ford G, Holton K, Pandarinathan L, Lapierre J, Stanney W, Bulock K, Shaw S, Libertine L, Fettes K, Khvorova A, Kaushal S, Pavco P (2013) Novel hydrophobically modified asymmetric RNAi compounds (sdrxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther 29:855-864
11. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, Giese K, Kaufmann J (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705-2716
12. Yuan ZP, Wu XL, Liu C, Xu GX, Wu ZW (2012) Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression. Hum Gene Ther 23:521-532
13. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J (2007) Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 35:5886-5897
14. Dallas A, Ilves H, Shorenstein J, Judge A, Spitler R, Contag C, Wong SP, Harbottle RP, MacLachlan I, Johnston BH (2013) Minimal length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice. Mol Ther Nucleic Acids 2, e123
15. Gao S, Dagnaes-Hansen F, Nielsen EJB, Wengel J, Besenbacher F, Howard KA, Kjems J (2009) The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17:1225-1233
16. Tsui NBY, Ng EKO, Lo YMD (2002) Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 48:1647-1653
17. Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ (2006) Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res 34:1669-1675
18. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178
19. Zeng Y, Cullen BR (2002) RNA interference in human cells is restricted to the cytoplasm. RNA 8:855-860
20. Gagnon KT, Li LD, Chu YJ, Janowski BA, Corey DR (2014) RNAi factors are present and active in human cell nuclei. Cell Rep 6:211-221
21. Robb GB, Brown KM, Khurana J, Rana TM (2005) Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol 12:133-137
22. Roberts TC (2014) The MicroRNA biology of the mammalian nucleus. Mol Ther Nucleic Acids 3, e188
23. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen DL, Zoncu R, Buganim Y, Schroeder A, Langer R, Anderson DG (2013) Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31:653-658
24. Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias (vol 115, pg 209, 2003). Cell 115:505
25. Schwarz DS, Hutvagner G, Du T, Xu ZS, Aronin N, Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208
26. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS (2006) Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-1187
27. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS (2004) Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 101:1892-1897
28. Persengiev SP, Zhu XC, Green MR (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10:12-18
29. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G (2005) Sequencespecific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270
30. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457-462
31. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19:89-101
32. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529
33. Doench JG, Petersen CP, Sharp PA (2003) siRNAs can function as miRNAs. Genes Dev 17:438-442
34. Hong J, Qian ZK, Shen SY, Min TS, Tan C, Xu JF, Zhao YC, Huang WD (2005) High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse. Biochem J 390:675-679
35. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541
36. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D (2007) Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449:745-747
37. Snead NM, Escamilla-Powers JR, Rossi JJ, McCaffrey AP (2013) 5′ unlocked nucleic acid modification improves siRNA targeting. Mol Ther Nucleic Acids 2, e103
38. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Hojland T, Abramov M, Van Aerschot A, Odadzic D, Smicius R, Haas J, Andree C, Barman J, Wenska M, Srivastava P, Zhou CZ, Honcharenko D, Hess S, Muller E, Bobkov GV, Mikhailov SN, Fava E, Meyer TF, Chattopadhyaya J, Zerial M, Engels JW, Herdewijn P, Wengel J, Kjems J (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 37:2867-2881
39. Choung S, Kim YJ, Kim S, Park HO, Choi YC (2006) Chemical modification of siRNAs to improve serum stability without loss of effi-cacy. Biochem Biophys Res Commun 342:919-927
40. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, Tuschl T (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105
41. Geary RS, Yu RZ, Levin AA (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562-573
42. Overhoff M, Sczakiel G (2005) Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep 6:1176-1181
43. Krieg AM, Stein CA (1995) Phosphorothioate oligodeoxynucleotides: antisense or antiprotein? Antisense Res Dev 5:241
44. Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9:1034-1048
45. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975
46. Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589-595
47. Hall AHS, Wan J, Shaughnessy EE, Shaw BR, Alexander KA (2004) RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 32:5991-6000
48. Hohjoh H (2002) RNA interference (RNAi) induction with various types of synthetic oli without interruption of the endogenous microRNA pathway. Nature 449:745-747
49. Snead NM, Escamilla-Powers JR, Rossi JJ, McCaffrey AP (2013) 5′ unlocked nucleic acid modification improves siRNA targeting. Mol Ther Nucleic Acids 2, e103
50. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Hojland T, Abramov M, Van Aerschot A, Odadzic D, Smicius R, Haas J, Andree C, Barman J, Wenska M, Srivastava P, Zhou CZ, Honcharenko D, Hess S, Muller E, Bobkov GV, Mikhailov SN, Fava E, Meyer TF, Chattopadhyaya J, Zerial M, Engels JW, Herdewijn P, Wengel J, Kjems J (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 37:2867-2881
51. Choung S, Kim YJ, Kim S, Park HO, Choi YC (2006) Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 342:919-927
52. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, Tuschl T (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105
53. Geary RS, Yu RZ, Levin AA (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562-573
54. Overhoff M, Sczakiel G (2005) Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep 6:1176-1181
55. Krieg AM, Stein CA (1995) Phosphorothioate oligodeoxynucleotides: antisense or antiprotein? Antisense Res Dev 5:241
56. Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9:1034-1048
57. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975
58. Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589-595
59. Hall AHS, Wan J, Shaughnessy EE, Shaw BR, Alexander KA (2004) RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 32:5991-6000
60. Hohjoh H (2002) RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. FEBS Lett 521:195-199
61. Boutla A, Delidakis C, Livadaras I, Tabler M (2003) Variations of the 3′ protruding ends in synthetic short interfering RNA (siRNA) tested by microinjection in Drosophila embryos. Oligonucleotides 13:295-301
62. Rettig GR, Behlke MA (2012) Progress toward in vivo use of siRNAs-II. Mol Ther 20:483-512
63. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K (2008) Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 36:2136-2151
64. Allerson CR, SioufiN, Jarres R, Prakash TP, Naik N, Berdeja A, Wanders L, Griffey RH, Swayze EE, Bhat B (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48:901-904
65. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS (2006) Position-specific chemical modification of siRNAs reduces “offtarget” transcript silencing. RNA 12:1197-1205
66. Judge AD, Bola G, Lee AC, MacLachlan I (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13:494-505
67. Hoshika S, Minakawa N, Kamiya H, Harashima H, Matsuda A (2005) RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. FEBS Lett 579:3115-3118
68. Dande P, Prakash TP, SioufiN, Gaus H, Jarres R, Berdeja A, Swayze EE, Griffey RH, Bhat B (2006) Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J Med Chem 49:1624-1634
69. Watts JK, Choubdar N, Sadalapure K, Robert F, Wahba AS, Pelletier J, Pinto BM, Damha MJ (2007) 2′-fluoro-4′-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res 35:1441-1451
70. Langkjaer N, Pasternak A, Wengel J (2009) UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 17:5420-5425
71. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439-447
72. Mook OR, Baas F, de Wissel MB, Fluiter K (2007) Evaluation of locked nucleic acidmodified small interfering RNA in vitro and in vivo. Mol Cancer Ther 6:833-843
73. Morita K, Hasegawa C, Kaneko M, Tsutsumi S, Sone J, Ishikawa T, Imanishi T, Koizumi M (2002) 2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett 12:73-76
74. Xia J, Noronha A, Toudjarska I, Li F, Akinc A, Braich R, Frank-Kamenetsky M, Rajeev KG, Egli M, Manoharan M (2006) Gene silencing activity of siRNAs with a ribodifluorotoluyl nucleotide. ACS Chem Biol 1:176-183
75. Liu J, Pendergraff H, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, Manoharan M, Hu J, Corey DR (2013) RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res 41:8788-8801
76. Chorn G, Zhao L, Sachs AB, Flanagan WM, Lim LP (2010) Persistence of seed-based activity following segmentation of a microRNA guide strand. RNA 16:2336-2340
77. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717
78. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005-1015
79. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839-849
80. Dohmen C, Frohlich T, Lachelt U, Rohl I, Vornlocher HP, Hadwiger P, Wagner E (2012) Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol Ther Nucleic Acids 1, e7
81. Jeong JH, Mok H, Oh YK, Park TG (2009) siRNA conjugate delivery systems. Bioconjug Chem 20:5-14
82. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I (2006) RNAi-mediated gene silencing in non-human primates. Nature 441:111-114
83. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149-1157
84. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 16:734-740
85. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A (2014) PEG—a versatile conjugating ligand for drugs and drug delivery systems. J Control Release 192:67-81
86. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG (2006) PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116:123-129
87. Iversen F, Yang C, Dagnaes-Hansen F, Schaffert DH, Kjems J, Gao S (2013) Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3:201-209
88. Ezzat K, El Andaloussi S, Abdo R, Langel U (2010) Peptide-based matrices as drug delivery vehicles. Curr Pharm Des 16:1167-1178
89. Verdurmen WPR, Brock R (2011) Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci 32:116-124
90. Chiu YL, Ali A, Chu CY, Cao H, Rana TM (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11:1165-1175
91. Muratovska A, Eccles MR (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558:63-68
92. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM (2004) Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 24:10040-10046
93. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BS, Gait MJ, Lindsay MA (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18:1450-1459
94. Rensen PCN, Sliedregt LAJM, Ferns A, Kieviet E, van Rossenberg SMW, van Leeuwen SH, van Berkel TJC, Biessen EAL (2001) Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 276:37577-37584
95. Biessen EAL, Sliedregt-Bol K, Hoen PACT, Prince P, Van der Bilt E, Valentijn ARPM, Meeuwenoord NJ, Princen H, Bijsterbosch MK, Van der Marel GA, Van Boom JH, Van Berkel TJC (2002) Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug Chem 13:295-302
96. Prakash TP, Graham MJ, Yu JH, Carty R, Low A, Chappell A, Schmidt K, Zhao CG, Aghajan M, Murray HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo SL, Monia BP, Swayze EE, Seth PP (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796-8807
97. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH (2013) Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5:209ra152
98. Zheng D, Giljohann DA, Chen DL, Massich MD, Wang XQ, Iordanov H, Mirkin CA, Paller AS (2012) Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A 109:11975-11980
99. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA (2009) Gene regulation with polyvalent siRNA-nanoparticle conjugates. Journal of the American Chemical Society 131:2072
100. Behr JP (1997) The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 51:34-36
101. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, De Smedt SC, Behe M, Kissel T (2009) Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138:148-159
102. Wang XL, Xu RZ, Lu ZR (2009) A peptidetargeted delivery system with pH-sensitive amphiphilic cell membrane disruption for effi-cient receptor-mediated siRNA delivery. J Control Release 134:207-213
103. Wagner E (2012) Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res 45:1005-1013
104. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang QQ, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32
105. Troiber C, Edinger D, Kos P, Schreiner L, Klager R, Herrmann A, Wagner E (2013) Stabilizing effect of tyrosine trimers on pDNA and siRNA polyplexes. Biomaterials 34:1624-1633
106. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433
107. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070
108. Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, Heidel JD (2004) Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrincontaining polymers. Curr Med Chem 11:179-197
109. Shen JL, Kim HC, Su H, Wang F, Wolfram J, Kirui D, Mai JH, Mu CF, Ji LN, Mao ZW, Shen HF (2014) Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 4:487-497
110. Godinho BMDC, Ogier JR, Quinlan A, Darcy R, Griffin BT, Cryan JF, Driscoll CM (2014) PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability. Int J Pharm 473:105-112
111. Meyer M, Dohmen C, Philipp A, Kiener D, Maiwald G, Scheu C, Ogris M, Wagner E (2009) Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNApolymer conjugate. Mol Pharm 6:752-762
112. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection—a highly efficient, lipid-mediated DNAtransfection procedure. Proc Natl Acad Sci U S A 84:7413-7417
113. Tam YY, Chen S, Cullis PR (2013) Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5:498-507
114. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007
115. Semple SC, Akinc A, Chen JX, Sandhu AP, Mui BL, Cho CK, Sah DWY, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen QM, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172-176
116. Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen JX, Du XY, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ (2012) Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51:8529-8533
117. Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J, Manoharan M, Cullis PR, Macvicar BA (2013) Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2, e136
118. Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967-977
119. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26:561-569
120. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Rohl I, Leshchiner ES, Langer R, Anderson DG (2009) Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17:872-879
121. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 107:1864-1869
122. Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V (2012) Systemic RNAimediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 1, e4
123. Dahlman JE, Barnes C, Khan OF, Thiriot A, Jhunjunwala S, Shaw TE, Xing YP, Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL, Yin H, Racie T, Dong YZ, Jiang S, Seedorf D, Dave A, Sandhu KS, Webber MJ, Novobrantseva T, Ruda VM, Lytton-Jean AKR, Levins CG, Kalish B, Mudge DK, Perez M, Abezgauz L, Dutta P, Smith L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M, Danino D, Tuder RM, von Andrian UH, Akinc A, Panigrahy D, Schroeder A, Koteliansky V, Langer R, Anderson DG (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol 9:648-655
124. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730-2736
125. Mae M, El Andaloussi S, Lehto T, Langel U (2009) Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 6:1195-1205
126. Heitz F, Morris MC, Divita G (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195-206
127. Deshayes S, Morris M, Heitz F, Divita G (2008) Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 60:537-547
128. Simeoni F, Morris MC, Heitz F, Divita G (2003) Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31:2717-2724
129. Weller K, Lauber S, Lerch M, Renaud A, Merkle HP, Zerbe O (2005) Biophysical and biological studies of end-group-modified derivatives of Pep-1. Biochemistry 44:15799-15811
130. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, Divita G (2006) A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758:384-393
131. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17:95-103
132. Kim WL, Christensen LV, Jo S, Yockman JW, Jeong JH, Kim YH, Kim SW (2006) Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 14:343-350
133. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, Sugiura Y (2001) Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12:1005-1011
134. Lehto T, Ezzat K, Langel U (2011) Peptide nanoparticles for oligonucleotide delivery. Prog Mol Biol Transl Sci 104:397-426
135. Andaloussi SEL, Lehto T, Mager I, Rosenthal-Aizman K, Oprea II, Simonson OE, Sork H, Ezzat K, Copolovici DM, Kurrikoff K, Viola JR, Zaghloul EM, Sillard R, Johansson HJ, Hassane FS, Guterstam P, Suhorutsenko J, Moreno PMD, Oskolkov N, Halldin J, Tedebark U, Metspalu A, Lebleu B, Lehtio J, Smith CIE, Langel U (2011) Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 39:3972-3987
136. Ezzat K, Zaghloul EM, Andaloussi SEL, Lehto T, El-Sayed R, Magdy T, Smith CIE, Langel U (2012) Solid formulation of cellpenetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. J Control Release 162:1-8
137. Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27:567-571
138. Michiue H, Eguchi A, Scadeng M, Dowdy SF (2009) Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8:2306-2313
139. Corey DR (2007) RNA learns from antisense. Nat Chem Biol 3:8-11
140. Crombez L, Morris MC, Dufort S, Aldrian-Herrada G, Nguyen Q, Mc Master G, Coll JL, Heitz F, Divita G (2009) Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 37:4559-4569
141. Morris MC, Chaloin L, Choob M, Archdeacon J, Heitz F, Divita G (2004) Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 11:757-764
142. Morris MC, Gros E, Aldrian-Herrada G, Choob M, Archdeacon J, Heitz F, Divita G (2007) A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 35, e49
143. Khalil IA, Futaki S, Niwa M, Baba Y, Kaji N, Kamiya H, Harashima H (2004) Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther 11:636-644
144. Lehto T, Abes R, Oskolkov N, Suhorutsenko J, Copolovici DM, Mager I, Viola JR, Simonson OE, Ezzat K, Guterstam P, Eriste E, Smith CIE, Lebleu B, El Andaloussi S, Langel U (2010) Delivery of nucleic acids with a stearylated (RxR)(4) peptide using a non-covalent co-incubation strategy. J Control Release 141:42-51
145. Lehto T, Simonson OE, Mager I, Ezzat K, Sork H, Copolovici DM, Viola JR, Zaghloul EM, Lundin P, Moreno PMD, Mae M, Oskolkov N, Suhorutsenko J, Smith CIE, Andaloussi SEL (2011) A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 19:1457-1467
146. Ezzat K, El Andaloussi S, Zaghloul EM, Lehto T, Lindberg S, Moreno PMD, Viola JR, Magdy T, Abdo R, Guterstam P, Sillard R, Hammond SM, Wood MJA, Arzumanov AA, Gait MJ, Smith CIE, Hallbrink M, Langel U (2011) PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 39:5284-5298
147. Oskolkov N, Arukuusk P, Copolovici DM, Lindberg S, Margus H, Padari K, Pooga M, Langel U (2011) NickFects, phosphorylated derivatives of transportan 10 for cellular delivery of oligonucleotides. Int J Pept Res Ther 17:147-157